First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Published:2023-09 Issue:9 Volume:24 Page:989-1001
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Özgüroğlu Mustafa,Kilickap Saadettin,Sezer Ahmet,Gümüş Mahmut,Bondarenko Igor,Gogishvili Miranda,Nechaeva Marina,Schenker Michael,Cicin Irfan,Ho Gwo Fuang,Kulyaba Yaroslav,Zyuhal Kasimova,Scheusan Roxana-Ioana,Garassino Marina Chiara,He Xuanyao,Kaul Manika,Okoye Emmanuel,Li Yuntong,Li Siyu,Pouliot Jean-Francois,Seebach Frank,Lowy Israel,Gullo Giuseppe,Rietschel Petra

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. The biology and management of non-small cell lung cancer;Herbst;Nature,2018

3. SEER cancer statistics review, 1975–2018, based on November 2020 SEER data submission, posted to the SEER web site, April 2021;Howlader,2021

4. Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice;Burova;Mol Cancer Ther,2017

5. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial;Sezer;Lancet,2021

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of immunotherapy in early-stage and metastatic NSCLC;Pathology and Oncology Research;2024-07-04

2. Immunotherapy in non-small cell lung cancer: current status, advances and challenges;Minerva Respiratory Medicine;2024-07

3. Advancements in non-small cell lung cancer treatment: from early to advanced stages;Oncology in Clinical Practice;2024-06-24

4. Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations;American Society of Clinical Oncology Educational Book;2024-06

5. Case report: Long-term intracranial effect of zimberelimab monotherapy following surgical resection of high PD-L1-expressing brain metastases from NSCLC;Frontiers in Oncology;2024-05-10